TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessment of function, nutrition and cognition, with attention to frailty and muscle loss and consideration of supports such as resistance training and adequate protein.
The American Geriatrics Society (AGS) has published a framework to help clinicians prescribe obesity medications to older adults while accounting for age-related health risks. The case-based guidance applies the Geriatrics 5Ms to therapies including GLP-1 medications and emphasizes assessing function, nutrition and cognition before treatment.
The paper, titled Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing, was published in the Journal of the American Geriatrics Society. Developed by the AGS Healthy Aging Special Interest Group, it uses clinical cases to discuss how clinicians can approach obesity medication decisions for older patients.
The authors note that these medicines may offer benefits for weight management and glycemic control, among other health conditions, but older adults are underrepresented in clinical trials. The framework therefore directs clinicians to consider possible risks including sarcopenia, frailty, lean muscle loss, malnutrition and dehydration rather than basing decisions on weight alone.
Before prescribing, the paper recommends assessing a patient’s functional status, nutritional adequacy and cognitive impairment. It also describes healthy habits such as resistance training and adequate dietary protein as co-interventions. For some patients, care may involve a team that includes a registered dietitian, physical therapist, fitness trainer or behavioral health professional.
Balancing Weight Goals With Function
The framework addresses a clinical challenge: a medication’s potential benefits for weight and blood sugar need to be weighed against the possibility that an older patient could lose lean muscle or have difficulty maintaining adequate nutrition and hydration. Those concerns may matter to mobility, strength and day-to-day function, not just a number on the scale.
By making function, nutrition and cognition part of the prescribing discussion, the guidance offers clinicians a way to consider whether treatment fits an individual patient’s health priorities and circumstances. The emphasis on resistance exercise and protein intake also presents prescribing as part of a broader care plan rather than a medication-only decision. The paper is a framework for clinical consideration, not evidence that every older adult should or should not receive these medicines.
Popular right now
TCL QM64L 85-Inch QD-Mini LED 4K Smart Fire TV
TCL T7 Series 85-Inch 4K 144Hz QLED Smart Google TV
Ninja DualZone 6-in-1 Air Fryer, 8-Qt, Grey, DZ801
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The AGS framework is organized around its Geriatrics 5Ms: Mind, Mobility, Medications, Multicomplexity and Matters Most. These categories bring cognitive health, movement, medication decisions, multiple health conditions and the patient’s own priorities into the discussion. The paper applies that approach to incretin therapy, which includes GLP-1 medications that act through gut-derived hormonal pathways.
The article does not present a new clinical trial or report treatment outcomes. Instead, it offers a practical, case-based approach for clinicians amid the use of obesity medications and a noted evidence gap: older adults have been underrepresented in trials. Its recommendations focus on individualized assessment and supportive care in this population.
“Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing”
— Elias M. Wisdom and co-authors
Evidence Gaps and Patient Risks
The framework does not establish how obesity medications affect every older adult or quantify the likelihood of the risks it identifies. The source report provides no trial results, comparative outcome data, or specific estimates for muscle loss, malnutrition or dehydration. It says older adults are underrepresented in clinical trials, leaving uncertainty about how broadly findings from other populations apply to them.
The supplied material also does not specify which patients should receive a particular medication, how clinicians should adjust doses, or how often patients should be monitored. Those decisions remain individualized; the paper’s recommendations are presented as considerations for care, not a universal prescribing rule.
How Clinicians May Use the Guidance
The paper is available in the Journal of the American Geriatrics Society and is intended to help clinicians apply geriatric principles in prescribing decisions. In practice, its proposed approach points to pretreatment evaluation and discussion of the patient’s goals, nutrition, functional abilities and other health conditions, with relevant support added to the care plan.
The source report does not announce a follow-up study, implementation timeline or additional AGS action. Further evidence on outcomes in older adults would help clarify how the medicines’ benefits and risks vary across patients; the report provides no date for such research or additional guidance.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians considering obesity medications for older adults. It applies the Geriatrics 5Ms to prescribing decisions.
Which medicines does the framework address?
The paper discusses obesity medications, including GLP-1 medicines and other incretin therapies. The supplied report does not name specific products or provide a drug-by-drug comparison.
What should clinicians assess before treatment?
The framework recommends assessing functional status, nutritional adequacy and cognitive impairment, while considering risks such as frailty, muscle loss, malnutrition and dehydration.
Does the framework recommend exercise or nutrition support?
It identifies resistance training and adequate dietary protein as co-interventions. It also says some patients may benefit from a team that includes nutrition, physical therapy, fitness or behavioral health professionals.
Does the paper prove these drugs are safe or unsafe for all older adults?
No. The report describes a clinical framework, not a trial establishing safety or effectiveness for every older patient. It also notes that older adults are underrepresented in clinical trials.
Source: medicalxpress.com
